Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers create new cell screening method for immunotherapy cancer treatments

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

New tool combines drugs to target kinase dependency in cancer

New tool combines drugs to target kinase dependency in cancer

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers establish safety, dosing of new drug for treating blood cancers

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

New study reveals protein's critical role in development and progression of AML

New study reveals protein's critical role in development and progression of AML

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

Stem cell transplantation improves outcomes in children with rare form of chronic blood cancer

Stem cell transplantation improves outcomes in children with rare form of chronic blood cancer

Genetic variation influences survival in patients with multiple myeloma

Genetic variation influences survival in patients with multiple myeloma

Dartmouth researchers perform first total syntheses of compounds involved in rapid cell death in leukemia

Dartmouth researchers perform first total syntheses of compounds involved in rapid cell death in leukemia

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Americord Registry reports new policy for client reimbursement

Americord Registry reports new policy for client reimbursement

Noninvasive prenatal screening could detect maternal cancer

Noninvasive prenatal screening could detect maternal cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.